ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2008
Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 107 citations in OpenAlex.
- Potential of Adora2b as an immunotherapeutic target for gastric cancer.Frontiers in immunology · 2025Review
- CD73 deficiency does not aggravate angiotensin II-induced aortic inflammation in mice.Scientific reports · 2023Article
- Adenosine metabolized from extracellular ATP ameliorates organ injury by triggering ARespiratory research · 2023Article
- Alternative adenosine Receptor activation: The netrin-Adora2b link.Frontiers in pharmacology · 2022Review
- Cellular Stress and Molecular Responses in Bladder Ischemia.International journal of molecular sciences · 2021Review
- Role of Purinergic Signalling in Endothelial Dysfunction and Thrombo-Inflammation in Ischaemic Stroke and Cerebral Small Vessel Disease.Biomolecules · 2021Review
- Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?International journal of molecular sciences · 2021Review
- κ-opioid receptor agonists may alleviate intestinal damage in cardiopulmonary bypass rats by inhibiting the NF-κB/HIF-1α pathway.Experimental and therapeutic medicine · 2020Article
- Hypoxia-Inducible Factor-2α Reprograms Liver Macrophages to Protect Against Acute Liver Injury Through the Production of Interleukin-6.Hepatology (Baltimore, Md.) · 2020Article
- Dysregulation of ectonucleotidase-mediated extracellular adenosine during postmenopausal bone loss.Science advances · 2019Article
- Be Aware of Aggregators in the Search for Potential HumanMolecules (Basel, Switzerland) · 2018Article
- Adenosine metabolism, immunity and joint health.Biochemical pharmacology · 2018Review
- Infant cardiopulmonary bypass: CD73 kinetics, association with clinical outcomes, and influence on serum adenosine production capacity.Pediatric research · 2018Article
- Targeting Hypoxia Signaling for Perioperative Organ Injury.Anesthesia and analgesia · 2018Review
- Proximal Tubule CD73 Is Critical in Renal Ischemia-Reperfusion Injury Protection.Journal of the American Society of Nephrology : JASN · 2017Article
- Hypoxia-inducible factors as molecular targets for liver diseases.Journal of molecular medicine (Berlin, Germany) · 2016Review
- Inhibition of P38 MAPK Downregulates the Expression of IL-1β to Protect Lung from Acute Injury in Intestinal Ischemia Reperfusion Rats.Mediators of inflammation · 2016Article
- CD39 improves survival in microbial sepsis by attenuating systemic inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.Hypoxia (Auckland, N.Z.) · 2015Review
- Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness.Metabolism: clinical and experimental · 2014Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Extracellular adenosine has been implicated as an innate antiinflammatory metabolite, particularly during conditions of limited oxygen availability such as ischemia. Because extracellular adenosine generation is primarily produced via phosphohydrolysis from its precursor molecule adenosine-monophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contribution of CD73-dependent adenosine production in modulation of intestinal ischemia-reperfusion (IR) injury. Following transcriptional and translational profiling of intestinal tissue that revealed a prominent induction of murine CD73, we next determined the role of CD73 in protection against intestinal IR injury. Interestingly, pharmacological inhibition or targeted gene deletion of CD73 significantly enhanced not only local intestinal injury, but also secondary organ injury, following IR as measured by intestinal and lung myeloperoxidase, aspartate and alanine aminotransferase, interleukin (IL) -1, IL-6, and histological injury. To confirm the role of CD73 in intestinal adenosine production, we measured adenosine tissue levels and found that they were increased with IR injury. In contrast, CD73-deficient (cd73(-/-)) mice had lower adenosine levels at baseline and no increase with IR injury. Finally, reconstitution of cd73(-/-) mice or treatment of wild-type mice with soluble 5'-nucleotidase was associated with significantly lower levels of injury. These data reveal a previously unrecognized role of CD73 in attenuating intestinal IR-mediated injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.